Lunai Bioworks will execute a 1-for-8 reverse stock split to increase its stock price and regain Nasdaq compliance with minimum bid price requirements. The reverse split reduces outstanding shares from approximately 36.3 million to 4.5 million and follows a previous 1-for-10 reverse split in September 2025.